Abstract
The diverse members of the CCN family now designated as CCN1(CYR61), CCN2 (CTGF), CCN3(NOV), CCN4(WISP1), CCN5(WISP2), CCN6(WISP3) are a conserved matricellular family of proteins exhibiting a spectrum of functional properties throughout all organs in the body. Interaction with cell membrane receptors such as integrins trigger intracellular signaling pathways. Proteolytically cleaved fragments (constituting the active domains) can be transported to the nucleus and perform transcriptional relevant functional activities. Notably, as also found in other protein families some members act opposite to others creating a system of functionally relevant checks and balances. It has become apparent that these proteins are secreted into the circulation, are quantifiable, and can serve as disease biomarkers. How they might also serve as homeostatic regulators is just becoming appreciated. In this review I have attempted to highlight the most recent evidence under the subcategories of cancer and non-cancer relevant that could lead to potential therapeutic approaches or ideas that can be factored into clinical advances. I have added my own personal perspective on feasibility.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackar L, Casjens S, Andreas A et al. (2021) Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study. Mol Oncol 15:2877–2890. https://doi.org/10.1002/1878-0261.13099
Ahmed KA, Hasib TA, Paul SK et al. (2021) Potential role of CCN Proteins in breast cancer: therapeutic advances and perspectives. Curr Oncol 28:4972–4985. https://doi.org/10.3390/curroncol28060417
Alami T, Liu J-L (2021) Metabolic effects of CCN5/WISP2 gene deficiency and transgenic overexpression in mice. Int J Mol Sci 22:13418. https://doi.org/10.3390/ijms222413418
Banerjee SK, Banerjee S (2012) CCN5/WISP-2: a micromanager of breast cancer Progression. J Cell Commun Signal 6:63–71. https://doi.org/10.1007/s12079-012-0158-2
Banerjee SK, Maity G, Haque I et al. (2016) human pancreatic cancer progression: an anarchy among CCN-siblings. J Cell Commun Signal 10:207–216. https://doi.org/10.1007/s12079-016-0343-9
Barbe MF, Hilliard BA, Amin M et al. (2020) Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy. J Orthop Res 38:2396–2408. https://doi.org/10.1002/jor.24709
Barbe MF, Amin M, Gingery A et al. (2021) Blocking CCN2 preferentially Inhibits osteoclastogenesis induced by repetitive high force bone loading. Connect Tiss Res 62:115–132. https://doi.org/10.1080/03008207.2020.1788546
Barchetta I, Cimini FA, Capoccia D et al. (2017) WISP1 Is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocrine Soc 1:660–670. https://doi.org/10.1210/js.2017-00108
Bashir SM, Rather GA, Patrício A et al. (2022) Chitosan Nanoparticles: a versatile platform for biomedical applications. Materials 15:6521. https://doi.org/10.3390/ma15196521
Betageri KR, Link PA, Haak AJ et al. (2023) The matricellular protein CCN3 supports lung endothelial homeostasis and function. Am J Physiol Lung Cell Mol Physiol 324:L154–L168. https://doi.org/10.1152/ajplung.00248.2022. (Epub 2022 Dec 27)
Bhat IP, Rather TB, Maqbool I et al. (2022) Connective tissue growth factor expression hints at aggressive nature of colorectal cancer. World J Gastroenterol 28:547–569. https://doi.org/10.3748/wjg.v28.i5.547
Birch J, Gil J (2020) Senescence and the SASP: many therapeutic avenues. Genes Dev 34:1565–1576. https://doi.org/10.1101/gad.343129.120
Birkeness LB, Snigdha Banerjee S, Quadir M, Banerjee SK (2023) The role of CCNs in controlling cellular communication in the tumor microenvironment. J Cell Commun Signal 17:35–45. https://doi.org/10.1007/s12079-022-00682-2
Blokland KEC, Pouwels SD, Schuliga M, Knight DA, Burgess JK (2020) Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases. Clin Sci 134:2681–2706. https://doi.org/10.1042/CS20190893
Brown BA, Connolly GM, Mill CEJ et al. (2019) Aging differentially modulates the Wnt pro-survival signaling pathways in vascular smooth muscle cells. Aging Cell 18:e12844. https://doi.org/10.1111/acel.12844
Butler GS, Connor AR, Sounni NE et al. (2017) Degradomic and yeast 2-hybrid inactive catalytic domain substrate trap** identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). Matrix Biol 59:23–38. https://doi.org/10.1016/j.matbio.2016.07.006
Chai K-X, Chen Y-Q, Fan P-L et al. (2018) The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis. Medicine 97:34. https://doi.org/10.1097/MD.0000000000011775
Chang Z, Dang T, Meng X, Chai J (2022) The Role of CCN1 in esophageal adenocarcinoma: What we have learned from the lab. Cancer Control 29:1–9. https://doi.org/10.1177/10732748221074734
Chang A-C, Lin L-W, Chen Y-C et al. (2023) The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. Internat J Biol Sci 19:760–771. https://doi.org/10.7150/ijbs.77495
Crawford LJ, Irvine AE (2016) The role of the CCN family of proteins in blood cancers. J Cell Commun Signal 10:197–205. https://doi.org/10.1007/s12079-016-0342-x
Das A, Dhar K, Maity G, Sarkar S, Ghosh A (2017) Deficiency of CCN5/WISP-2- driven program in breast cancer promotes cancer epithelial cells to mesenchymal stem cells and breast cancer growth. Sci Rep 7:1220. https://doi.org/10.1038/s41598-017-00916-z
Das A, Haque I, Ray P et al (2021) CCN5 activation by free or encapsulated EGCG is required to render triple-negative breast cancer cell viability and tumor progression. Pharmacol Res Perspect 9:e00753. https://doi.org/10.1002/prp2.753
Davies SR, Davies ML, Sanders A et al. (2010) Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol 36:1129–36. https://doi.org/10.3892/ijo_00000595
Deng W, Fernandez A, McLaughlin SL et al. (2020) Cell Communication Network Factor 4 (CCN4/WISP1) shifts melanoma cells from a fragile proliferative state to a resilient metastatic state. Cell Mol Bioeng 13:45–60. https://doi.org/10.1007/s12195-019-00602-2
Di Micco R, Krizhanovsky V, Baker D, di Fagagna D (2021) Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Cell Biol 22:75–95. https://doi.org/10.1038/s41580-020-00314-w
Djomehri SI, Burman B, Gonzalez ME, Takayama S, Kleer CG (2019) A reproducible scaffold-free 3D organoid model to study neoplastic progression in breast cancer. J Cell Commun Signal 13:129–143. https://doi.org/10.1007/s12079-018-0498-7
Djomehri SI, Gonzalez ME, Leprevost FV et al. (2020) Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors. Nat Commun 11:1723. https://doi.org/10.1038/s41467-020-15283-z
Eguchi T, Okusha Y, Lu Y et al. (2023) Comprehensive method for exosome isolation and proteome analysis for detection of CCN factors in/on exosomes. Methods Mol Biol 2582:59–75. https://doi.org/10.1007/978-1-0716-2744
Ersoy GS, Ensari TA, Subas S et al. (2017) (2017) WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Fetal Neonatal Med 30:942–946. https://doi.org/10.1080/14767058.2016.1192118
Esaily HA, Serag DM, Rizk MS et al. (2021) Relationship between cellular communication network factor 1 (CCN1) and carotid atherosclerosis in patients with rheumatoid arthritis. Med J Malaysia 76:311–317 (PMID: 3403132)
Espinoza I, Yang L, Steen TV, et al. (2022) Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α6β1 drives endocrine resistance in breast cancer cells. Aging 14(1200–1213):2022
Fang F, Zhao W-Y, Li R-K et al. (2014) Silencing of WISP3 suppresses gastric cancer cell proliferation and metastasis and inhibits Wnt/βcatenin signalling. Int J Clin Exp Pathol 7:6447–6461. PMCID: 25400723 PMCID: PMC4230117
Feng T, Meng J, Kou S et al. (2019) CCN1-induced cellular senescence promotes heart regeneration. Circ 139:2495–2498. https://doi.org/10.1161/CIRCULATIONAHA.119.039530
Ferrand NF, Béreziat V, Moldes M et al. (2017) WISP1/CCN4 inhibits adipocyte differentiation through repression of PPARγ activity. Sci Rep 7:1749. https://doi.org/10.1038/s41598-017-01866-2
Ferrand N, Fert A, Morichon R et al. (2022) WISP2/CCN5 suppresses vasculogenic mimicry through inhibition of YAP/TAZ signaling in breast cancer cells. Cancers 14:1487. https://doi.org/10.3390/cancers14061487
Fernandez-Ruiz R, García-Alamán A, Esteban Y et al. (2020) Wisp1 is a circulating factor that stimulates proliferation of adult mouse and human beta cells. Nat Commun 11:5982. https://doi.org/10.1038/s41467-020-19657-1
Fernandez A, Deng W, McLaughlin SL et al. (2022) Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma. EMBO Rept 23:e54127. https://doi.org/10.15252/embr.202154127
Fiaturi N, Russo JW, Nielsen HC, Castellot JJ Jr (2018) CCN5 in alveolar epithelial proliferation and differentiation during neonatal lung oxygen injury. J Cell Commun Signal 12:217–229. https://doi.org/10.1007/s12079-017-0443-1
Fritah A, Saucier C, De Wever O et al. (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28:1114–1123. https://doi.org/10.1128/MCB.01335-07
Fu M, Peng D, Lan T et al. (2022) Multifunctional regulatory protein connective tissue growth factor (CTGF): a potential therapeutic target for diverse diseases. Acta Pharmaceutica Sinica B 12:1740e1760. https://doi.org/10.1016/j.apsb.2022.01.007
Ganguly A, Padhan DK, Sengupta A et al. (2023) CCN6 influences transcription and controls mitochondrial mass and muscle organization. FASEB J 37:e22815. https://doi.org/10.1096/fj.202201533R
Gao H, Yin F-F, Guan D-X et al. (2019) Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β-catenin/TCF/LEF signaling. Cell Prolif 52:e12583. https://doi.org/10.1111/cpr.12583
Giusti V, Scotlandi K (2021) CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology. J Cell Commun Signal 15:545–566. https://doi.org/10.1007/s12079-021-00631-5
Grünberg JR, Elvin J, Paul A et al. (2018) CCN5/WISP2 and metabolic diseases. J Cell Commun Signal 12:309–318. https://doi.org/10.1007/s12079-017-0437-z
Gui P, Bivonal TG (2022) Evolution of metastasis: new tools and insights. Trends Cancer 8:2. https://doi.org/10.1016/j.trecan.2021.11.002
Gysler SM, Drapkin R (2021) Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest 13:e147276. https://doi.org/10.1172/JCI147276
Hade MD, Suire CN, Suo Z (2021) Mesenchymal stem cell-derived exosomes: applications in regenerative medicine. Cells 10:1959. https://doi.org/10.3390/cells10081959
Haque I, Ghosh A, Acup S, Banerjee S et al. (2018) Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. BMC Cancer 18:99. https://doi.org/10.1186/s12885-018-3993-6
He M, Chen Z, Martin M et al. (2017) miR-483 targeting of CTGF suppresses endothelial-to-mesenchymal transition: therapeutic implications in Kawasaki Disease. Circ Res 120:354–65. https://doi.org/10.1161/CIRCRESAHA.116.310233
Hörbelt T, Tacke C, Markova M (2018) The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia 61:2054–2065. https://doi.org/10.1007/s00125-018-4636-9
Huang W, Pal A, Kleer CG (2012) On how CCN6 suppresses breast cancer growth and invasion. J Cell Commun Signal 6:5–10. https://doi.org/10.1007/s12079-011-0148-9
Huang W, Martin EE, Burman B, Gonzalez ME, Kleer CG (2016) The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells. Oncotarget 7:25180–25193. https://doi.org/10.18632/oncotarget.7734
Im S, Han JW, Park EJ et al. (2022) Suppression of choroidal neovascularization and epithelial-mesenchymal transition in retinal pigmented epithelium by adenoassociated virus-mediated overexpression of CCN5 in mice. PLoS One 17:e0269937. https://doi.org/10.1371/journal.pone.0269937
Janjanam J, Pano G, Wang R et al. (2021) Matricellular protein WISP2 is an endogenous inhibitor of collagen linearization and cancer metastasis. Cancer Res 81:5666–77. https://doi.org/10.1158/0008-5472.CAN-20-3982
Jeong D, Lee M-A, Li Y et al. (2016) Matricellular protein CCN5 reverses established cardiac fibrosis. J Am Coll Cardiol 67:1556–1568. https://doi.org/10.1016/j.jacc.2016
Jia H, Janjanam J, Wu SC et al. (2019) The tumor cell-secreted matricellular protein WISP1 drives pro-metastatic collagen linearization. EMBO J 38:e101302. https://doi.org/10.15252/embj.2018101302
Jiang R, Tang J, Zhang X et al. (2022) CCN1 promotes inflammation by inducing IL-6 production via a6b1/ PI3K/Akt/NF-kB pathway in autoimmune hepatitis. Front Immunol 13:e10671. https://doi.org/10.3389/fimmu.2022.810671
Johansson M, Tangruksa B, Heydarkhan-Hagvall S et al. (2022) Data mining identifies CCN2 and THBS1 as biomarker candidates for cardiac hypertrophy. Life 12:726. https://doi.org/10.3390/life12050726
Ju L, Su Y, Xu H et al. (2020) CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. Sci Repts 10:3201. https://doi.org/10.1038/s41598-020-60138-8
Jun J-I, Lau LF (2010) Cellular senescence controls fibrosis in wound healing. Aging 2:627–631. https://doi.org/10.18632/aging.100201
Jun J-II, Lau LF (2010b) The matricellular protein CCN1/CYR61 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 12:676–685. https://doi.org/10.1038/ncb2070
Jun J-I, Lau LF (2013) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945–963. https://doi.org/10.1038/nrd3599
Jun J-L, Lau LF (2017) CCN2 induces cellular senescence in fibroblasts. J Cell Commun Signal 11:15–23. https://doi.org/10.1007/s12079-016-0359-1
Jun IL, Lau LF (2020) CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling. Nat Commun 11:1242. https://doi.org/10.1038/s41467-020-15075-5
Jung TW, Kang C, Goh J et al. (2018) WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 233:6077–6087. https://doi.org/10.1002/jcp.26449
Karaskova E, Kubickova V, Velganova-Vegghova M et al. (2022) Circulating levels of WISP-1 (Wnt1-inducible signaling pathway protein 1) and other selected adipokines in children with inflammatory bowel disease. Physiol Res 71:275–284. https://doi.org/10.33549/physiolres.934854
Kleer CG, Zhang Y, Pan Q et al. (2004) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6:R110–R115. https://doi.org/10.1186/bcr755
Kleer CG (2016) Dual roles of CCN proteins in breast cancer progression. J Cell Commun Signal 10:217–222. https://doi.org/10.1007/s12079-016-0345-7
Klenotic PA, Zhang C, Lin Z (2021) Emerging roles of CCN proteins in vascular development and pathology. J Cell Commun Signal 10:251–257. https://doi.org/10.1007/s12079-016-0332-z
Klimontov VV, Bulumbaeva DM, Fazullina ON et al. (2020) Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal 14:101–109. https://doi.org/10.1007/s12079-019-00536-4
Kretzmann JA, Evans CW, Moses C et al. (2019) Tumour suppression by targeted intravenous nonviral CRISPRa using dendritic polymers. Chem Sci 10:7718. https://doi.org/10.1039/c9sc01432b
Kubota S, Kawaki H, Perbal B et al. (2021) Cellular communication network factor 3 in cartilage development and maintenance. J Cell Commun Signal 15:533–543. https://doi.org/10.1007/s12079-021-00629-z
Kubota S, Kawata K, Hattori T, Nishida T (2022) Molecular and genetic interactions between CCN2 and CCN3 behind their Yin-Yang collaboration. Int J Mol Sci 23:5887. https://doi.org/10.3390/ijms23115887
Kubota S (2023) Utilizing public molecular biological databases for CCN family research. Methods Mol Biol 2582:169–187. https://doi.org/10.1007/978-1-0716-2744-0_12
Kubota S, Kawaki H, Perbal B et al. (2023) Do not overwork: cellular communication network factor 3 for life in cartilage. J Cell Commun Signal. https://doi.org/10.1007/s12079-023-00723-4
Kular L, Pakradouni J, Kitabgi K, Laurent M, Martinerie C (2011) The CCN family: a new class of inflammation modulators? Biochimie 93:377–388. https://doi.org/10.1016/j.biochi.2010.11.010
Kulkarni T, Kurundkar AR, Kim T-I et al. (2020) The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respir Med 161:105821. https://doi.org/10.1016/j.rmed.2019.105821
Lake AC, Castellot JJ Jr (2003) CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Commun Signal 1:5. https://doi.org/10.1186/1478-811X-1-5
Lake AC, Bialik A, Walsh K, Castellot JJ Jr (2003) CCN5 Is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am J Pathol 162:219–231. https://doi.org/10.1016/S0002-9440(10)63813-8
Leask A (2010) Yin and Yang part deux: CCN5 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal 4:155–56. https://doi.org/10.1007/s12079-010-0092-0
Leask A (2020) Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis. J Cell Commun Signal 14:349–350. https://doi.org/10.1007/s12079-020-00568-1
Lee S, Ahad A, Luu M et al. (2019) CCN1–Yes-associated protein feedback loop regulates physiological and pathological angiogenesis. Mol Cell Biol 39:e00107-e119. https://doi.org/10.1128/MCB.00107-19
Leguit RJ, Raymakers RAP, Hebeda K, Goldschmeding R (2021) CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis. J Cell Commun Signal 15:25–56. https://doi.org/10.1007/s12079-020-00602-2
Li H, Li T, Wang H, He X et al. (2021) Diabetes promotes retinal vascular endothelial cell injury by inducing CCN1 expression. Front Cardiovasc Med 8:689318. https://doi.org/10.3389/fcvm.2021.689318
Li Y, Wang F, Liu T et al. (2022) (2022) WISP1 induces ovarian cancer via the IGF1/ αvβ3/Wnt axis. J Ovarian Res 15:94. https://doi.org/10.1186/s13048-022-01016-x
Li H, Yang T, Fei Z (2021) miR-26a-5p alleviates lipopolysaccharide-induced acute lung injury by targeting the connective tissue growth factor. Mol Med Rept 23:5. https://doi.org/10.3892/mmr.2020.11643
Li J, Ye L, Owen S, Weeks HP et al. (2015) Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review). Int J Mol Med 36:1451–1463. https://doi.org/10.3892/ijmm.2015.2390
Liu H, Dong W, Lin Z et al. (2013) CCN4 regulates vascular smooth muscle cell migration and proliferation. Mol Cells 36:112–118. https://doi.org/10.1007/s10059-013-0012-2
Liu D, Wang X, Zhang M et al. (2020) (2020) WISP1 alleviates lipid deposition in macrophages via the PPARγ/CD36 pathway in the plaque formation of atherosclerosis. J Cell Mol Med 24:11729–11741. https://doi.org/10.1111/jcmm.15783
Liu D, Zhang M, Tian J et al. (2022a) Wnt1 inducible signaling pathway protein 1 stabilizes atherosclerotic plaques in apolipoprotein E deficient mice via the focal adhesion kinase/mitogen activated extracellular signal regulated kinas/extracellular signal regulated kinase pathway. J Hyperten 4:1666–1681. https://doi.org/10.1097/HJH.000000000003195
Liu J, Chen S, Li Z et al. (2022) Hsa_circ_0040809 and hsa_circ_0000467 promote colorectal cancer cells progression and construction of a circRNA-miRNA-mRNA network. Front Genet 13:993727. https://doi.org/10.3389/fgene.2022.99372
Lukjanenko L, Karaz S, Stuelsatz P, Gurriaran-Rodriguez U et al. (2019) Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell 24:433–446. https://doi.org/10.1016/j.stem.2018.12.014
MacDonald IJ, Huang C-C, Liu S-C, Lin Y-Y, Tang C-H (2021) Targeting CCN Proteins in rheumatoid arthritis and osteoarthritis. Int J Mol Sci 22:4340. https://doi.org/10.3390/ijms22094340
Mahendiran T, Klingenberg R, Nanchen D et al. (2021) CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. Atherosclerosis 335:77–83. https://doi.org/10.1016/j.atherosclerosis.2021.09.019
Maiese K (2020) Prospects and perspectives for WISP1 (CCN4) in Diabetes Mellitus. Curr Neurovasc Res 17:327–331. https://doi.org/10.2174/1567202617666200327125257
Mbara KC, Devnarain N, Owira PO (2022) Potential role of polyphenolic flavonoids as senotherapeutic agents in degenerative diseases and geroprotection. Pharma Med 36:331–352. https://doi.org/10.1007/s40290-022-00444-w
McCallum L, Lu W, Price S et al. (2012) CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in chronic myeloid leukaemia. J. Cell Commun. Signal 6:27–35. https://doi.org/10.1007/s12079-011-0142-2
McCallum L, Irvine AE (2009) CCN3–a key regulator of the hematopoietic compartment. Blood Rev 23:79–85. https://doi.org/10.1016/j.blre.2008.07.002
Negri VA, Watt FM (2022) Understanding human epidermal stem cells at single-cell resolution. J Invest Dermatol 142:2061–2067. https://doi.org/10.1016/j.jid.2022.04.003
Nguyen MT, Lee M-A, Kim Y-K et al. (2022) IThe matricellular protein CCN5 induces apoptosis in myofibroblasts through SMAD7- mediated inhibition of NFκB. PLoS One 17:e0269735. https://doi.org/10.1371/journal.pone.02697352022
Nivison MP, Meier KE (2018) The role of CCN4/WISP-1 in the cancerous phenotype. Cancer Manage Res 10:2893–2903. https://doi.org/10.2147/CMAR.S133915
O’Connell GC, Alder ML, Smothers CG et al. (2020) Use of high-sensitivity digital ELISA improves the diagnostic performance of circulating brain-specific proteins for detection of traumatic brain injury during triage. Neurol Res 42:346–353. https://doi.org/10.1080/01616412.2020.1726588
Ohara Y, Enomoto A, Tsuyuk Y et al. (2020) Connective tissue growth factor produced by cancer-associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma. Oncol Rept 44:838–48. https://doi.org/10.3892/or.2020.7669
Okusha Y, Eguchi T (2023) Protocol for CRISPR/cas genome editing for investigating cell communication network. Methods Mol Biol 2582:157–167. https://doi.org/10.1007/978-1-0716-2744-0_11
Ono M, Inkson CA, Sonn R et al. (2013) WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS ONE 8:e71709. https://doi.org/10.1371/journal.pone.0071709
Padhan DK, Senupta A, Patra M et al. (2020) CCN6 regulates mitochondrial respiratory complex assembly and activity. FASEB J 34:12163–12176. https://doi.org/10.1096/fj.202000405RR
Pakradouni J, Le Goff WL, Calmel C et al. (2013) Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders. PLoS ONE 8(6):e66788. https://doi.org/10.1371/journal.pone.0066788
Peng L, Wei Y, Shao Y et al. (2021) The emerging roles of CCN3 protein in immune-related diseases. Mediators Inflam (hindawi) 2021:5576059. https://doi.org/10.1155/2021/5576059
Perbal B, Lazar N, Zambelli D (2009) Prognostic relevance of CCN3 in Ewing sarcoma. Hum Pathol 40:1479–1486. https://doi.org/10.1016/j.humpath.2009.05.008. (Epub 2009 Aug 19)
Perbal B, Tweedie S, Bruford E (2018) The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1–6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1–3 respectively. J Cell Commun Signal 12:625–629. https://doi.org/10.1007/s12079-018-0491-1
Corridgendum: Effective October 2018, the genes referred to as CYR61, CTGF, NOV and WISP1-3 will be respectively designated by the gene symbols CCN1-6 with corresponding gene names « cellular communication network factor 1–6 »
Perbal, (2023) Time has come to address the spatiotemporal combinatorial model for CCN proteins biological activitites by spatial transcriptomics and genome wide association studies. J Cell Commun Signal. https://doi.org/10.1007/s12079-023-00729-y
Picozzi V, Alseidi A, Winter J (2020) Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open 5:e000668. https://doi.org/10.1136/esmoopen-2019-000668
Piszczatowski RT, Lents NH (2016) Regulation of the CCN genes by vitamin D: a possible adjuvant therapy in the treatment of cancer and fibrosis. Cell Signal 28:1604–1613. https://doi.org/10.1016/j.cellsig.2016.07.009
Qin Z, He T, Guo C, Quan T (2022) Age-related downregulation of CCN2 is regulated by cell size in a YAP/TAZ-dependent manner in human dermal fibroblasts: Impact on dermal aging. JID Innov 2:100111. https://doi.org/10.1016/j.xjidi.2022.100111
Ren J, Wang X, Parry SN et al. (2022) Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes. J Cell Comm Signal 16:447–460. https://doi.org/10.1007/s12079-022-00667-1
Rebolledo D, Acuña Ma J, Brandan E (2021) Role of matricellular CCN proteins in skeletal muscle: focus on CCN2/CTGF and its regulation by vasoactive peptides. Int J Mol Sci 22:5234. https://doi.org/10.3390/ijms22105234
Resovi A, Borsotti P, Ceruti T et al. (2020) CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy. Cells 9:952. https://doi.org/10.3390/cells9040952
Ruiz-Fernández C, González-Rodríguez M, Abella V et al. (2022) WISP-2 modulates the induction of inflammatory mediators and cartilage catabolism in chondrocytes. Lab Invest 102:989–999. https://doi.org/10.1038/s41374-022-00793-9
Russo JW, Castellot JJ Jr (2010) CCN5: biology and pathophysiology. J Cell Commun Signal 4:119–130. https://doi.org/10.1007/s12079-010-0098-7
Sarkar S, Ghosh A, Banerjee S et al. (2017) CCN5/WISP-2 restores ER-∝ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogenesis 6:e340. https://doi.org/10.1038/oncsis.2017.43
Shen Y-S, Zhou Y-D, Chen H-Z et al. (2021) Targeting CTGF in Cancer: An Emerging therapeutic opportunity. Trends Cancer 7:511–24. https://doi.org/10.1016/j.trecan.2020.12.001
Shi H, Zhang C, Pasupuleti V (2017) CCN3 Regulates macrophage foam cell formation and atherosclerosis. Am J Pathol 187:1230–1237. https://doi.org/10.1016/j.ajpath.2017.01.020
Shi Z-Q, Chen Z-Y, Han Y, Zhu H-Y et al. (2020) WISP2 promotes cell proliferation via targeting ERK and YAP in ovarian cancer cells. J Ovar Res 13:85. https://doi.org/10.1186/s13048-020-00687-
Son S, Kim H, Lim H et al. (2023) CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. Cell Death Dis 14:81. https://doi.org/10.1038/s41419-023-05608-3
Song MH, Yoo J, Oh JG et al. (2022) Matricellular Protein CCN5 Gene transfer ameliorates cardiac and skeletal dysfunction in mdx/utrn (+/−) haploinsufficient mice by reducing fibrosis and upregulating utrophin expression. Front Cardiovasc Med 9:763544. https://doi.org/10.3389/fcvm.2022.763544
Song MH, Jo Y, Kim Y-K, Kook H, Jeong D, Park WJD (2022) The TSP-1 domain of the matricellular protein CCN5 is essential for its nuclear localization and anti-fibrotic function. PLoS ONE 17(4):e0267629. https://doi.org/10.1371/journal.pone.0267629
Srivastava A, Bencomo T, Das I, Lee CL (2023) Unravelling the landscape of skin cancer through single-cell transcriptomics. Translational Oncol 27:101557. https://doi.org/10.1016/j.tranon.2022.101557
Tacke C, Aleksandrova K, Rehfeldt M et al. (2018) Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal 12:539–548. https://doi.org/10.1007/s12079-017-0427-1
Takigawa M (2023) CCN proteins (Cellular Communication Network Factors): expanding their repertoire toward a new concept. In Takigawa M (ed.) CCN proteins: methods and protocols, methods in molecular biology 2582: 1–10 https://doi.org/10.1007/978-1-0716-2744-0_1
Thibout H, Martinerie CC, Creminon C et al. (2003) Characterization of human NOV in biological fluids: an enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab 88:327–336. https://doi.org/10.1210/jc.2002-020304
Tran MN, Kleer CG (2018) Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas. J Cell Commun Signal 12:13–19. https://doi.org/10.1007/s12079-018-0451-9
Tran M, Leflein SA, Gonzalez ME, Kleer CG (2022) The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas. J Cell Commun Signal 16:433–445. https://doi.org/10.1007/s12079-021-00657-9
Valentijn FA, Knoppert SN, Pissas GP et al. (2020) CCN2 aggravates the immediate oxidative stress–DNA damage response following renal ischemia–reperfusion injury. Antioxidants 10:2020. https://doi.org/10.3390/antiox10122020
Waldman M, Singh SP, Shen H-H, Alex R et al. (2022) Silencing the adipocytokine NOV: a novel approach to reversing oxidative stress-induced cardiometabolic dysfunction. Cells 11:3060. https://doi.org/10.3390/cells11193060
Wang A-r, Yan X-q, Zhang C et al. (2018) Characterization of Wnt1-inducible signalling protein-1 in obese children and adolescents. Curr Med Sci 38:868–874. https://doi.org/10.1007/s11596-018-1955-5
Wang D, Wang T, An Y et al. (2021) Nephroblastoma overexpressed protein (NOV) enhances 5-Fu-mediated inhibitory effect of colorectal cancer cell proliferation via JNK/AP-1/caspase-8/caspase-3 pathway. Discover Oncol 12:10. https://doi.org/10.1007/s12672-021-00403-y
Xu H, Liu C, Sun Z et al. (2015) CCN5 attenuates profibrotic phenotypes of fibroblasts through the Smad6-CCN2 pathway: potential role in epidural fibrosis. J Mol Med 36:123–129. https://doi.org/10.3892/ijmm.2015.2190
Xu Z, ** Y, Gao Z, Zeng Y, Du J et al. (2022) Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy 18:1152–1173. https://doi.org/10.1080/15548627.2021.1965712
Xu E-R, Lafita A, Bateman A, Hyvonen M (2020) The thrombospondin module 1 domain of the matricellular protein CCN3 shows an atypical disulfide pattern and incomplete CWR layers. Acta Crystall D Struct Biol 76:87–192. https://doi.org/10.1107/S2059798319016747
Yoon A, Im S, Lee J, Park D et al. (2018) The matricellular protein CCN5 inhibits fibrotic deformation of retinal pigment epithelium. PLoS ONE 13:e0208897. https://doi.org/10.1371/journal.pone.0208897
Zaykov V, Chaqour B (2021) The CCN2/CTGF interactome: an approach to understanding the versatility of CCN2/CTGF molecular activities. J Cell Commun Signal 15:567–580. https://doi.org/10.1007/s12079-021-00650-2
Zheng T, Chen H (2021) Resveratrol ameliorates the glucose uptake and lipid metabolism in gestational diabetes mellitus mice and insulin-resistant adipocytes via miR-23a-3p/NOV axis. Mol Immunol 137:163–173. https://doi.org/10.1016/j.molimm.2021.06.011
Zheng Y, Graeber MB (2022) Microglia and brain macrophages as drivers of glioma progression. Int J Mol Sci 23:15612. https://doi.org/10.3390/ijms232415612
Zhou Y-T, Yu Y-Q, Yang H, Yang H et al. (2022) Extracellular ATP promotes angiogenesis and adhesion of TNBC cells to endothelial cells via upregulation of CTGF. Cancer Sci 113:2457–2471. https://doi.org/10.1111/cas.15375
Zhu Y, Almuntashiri S, Han Y et al. (2020) The roles of CCN1/CYR61 in pulmonary diseases. Int J Mol Sci 21:7810. https://doi.org/10.3390/ijms21217810
Zolfaghari S, Kaasbøll OJ, Ahmed MS et al. (2022) Tissue distribution and transcriptional regulation of CCN5 in the heart after myocardial infarction. J Cell Commun Signal 16:377–395. https://doi.org/10.1007/s12079-021-00659-7
Zolfaghari S, Kaasbøll OJ, Monsen VT et al. (2023) The carboxyl-terminal TSP1-homology domain is the biologically active effector peptide of matricellular protein CCN5 that counteracts profibrotic CCN2. J Biol Chem 299(1):102803. https://doi.org/10.1016/j.jbc.2022.102803
Funding
No funding was received to assist with the preparation of this manuscript. The author has no competing interests to declare that are relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yeger, H. CCN proteins: opportunities for clinical studies—a personal perspective. J. Cell Commun. Signal. 17, 333–352 (2023). https://doi.org/10.1007/s12079-023-00761-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-023-00761-y